Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Onaiza J. Cadoret-Manier net worth and biography

Onaiza Cadoret-Manier Biography and Net Worth

EVP of Ionis Pharmaceuticals

Ms. Cadoret-Manier is executive vice president, chief global product strategy and operations officer at Ionis Pharmaceuticals. She is a member of Ionis’ executive leadership team, overseeing the company’s portfolio planning, global product strategy, medical affairs, market access and commercial strategy and operations functions. With 30 years of experience in life sciences, Ms. Cadoret-Manier is leading Ionis’ drive to integrate medical and commercial functions into the company.

She joined Ionis in 2020 as chief corporate development and commercial officer, where she led business development and commercial functions. Prior to Ionis, Ms. Cadoret-Manier was the chief commercial officer for Grail Biosciences, where she developed and executed a commercial strategy to prepare for the first ever early detection cancer screening test. She was previously vice president of the Respiratory Franchise at Genentech, where she built and managed a team of more than 400 employees responsible for commercializing medicines that generated $3 billion in revenue. She has held senior management positions overseeing corporate strategy, business development, alliances and marketing and sales for Genentech, Pfizer and Amylin Pharmaceuticals.

She has an MBA from the University of Chicago and a bachelor’s degree in economics from Queens College.

What is Onaiza J. Cadoret-Manier's net worth?: The estimated net worth of Onaiza J. Cadoret-Manier is at least $1.41 million as of January 17th, 2024. Ms. Cadoret-Manier owns 33,810 shares of Ionis Pharmaceuticals stock worth more than $1,406,158 as of April 27th. This net worth approximation does not reflect any other assets that Ms. Cadoret-Manier may own. Learn More about Onaiza J. Cadoret-Manier's net worth.
How do I contact Onaiza J. Cadoret-Manier?: The corporate mailing address for Ms. Cadoret-Manier and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Onaiza J. Cadoret-Manier's contact information.
Has Onaiza J. Cadoret-Manier been buying or selling shares of Ionis Pharmaceuticals?: Onaiza J. Cadoret-Manier has not been actively trading shares of Ionis Pharmaceuticals during the last ninety days. Most recently, Onaiza Cadoret-Manier sold 5,564 shares of the business's stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $50.42, for a transaction totalling $280,536.88. Following the completion of the sale, the executive vice president now directly owns 33,810 shares of the company's stock, valued at $1,704,700.20. Learn More on Onaiza J. Cadoret-Manier's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, insiders at the sold shares 28 times. They sold a total of 291,805 shares worth more than $14,352,782.01. The most recent insider tranaction occured on April, 16th when EVP Joseph Baroldi sold 4,006 shares worth more than $166,649.60. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 4/16/2024.

Onaiza J. Cadoret-Manier Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/17/2024	Sell	5,564	$50.42	$280,536.88	33,810

Onaiza J. Cadoret-Manier Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $41.59

$41.36

$42.28

50 Day Range

MA: $43.33

$40.68

$47.41

2 Week Range

Now: $41.59

$34.32

$54.44

Volume

556,043 shs

Average Volume

856,032 shs

Market Capitalization

$6.06 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39